2025
Oxidative Stress in People Living With HIV: Are Diverse Supplement Sources the Solution?
Amegashie E, Sikeola R, Tagoe E, Paintsil E, Torpey K, Quaye O. Oxidative Stress in People Living With HIV: Are Diverse Supplement Sources the Solution? Health Science Reports 2025, 8: e70824. PMID: 40330761, PMCID: PMC12054717, DOI: 10.1002/hsr2.70824.Peer-Reviewed Original ResearchHuman immunodeficiency virusAntiretroviral therapyMemory CD4 T cell responsesCD4 T cell responsesReducing human immunodeficiency virusOxidative stressAnimal modelsAntiretroviral therapy controlsLatent HIV infectionHIV-positive smokersT cell responsesReactive oxygen speciesCell linesT cell agingOxidation protein productsLow levels of antioxidantsIncreased oxidative stressWell-being of PLWHAntioxidant levelsHIV infectionImmunodeficiency virusOxidative stress levelsImmune overactivationOxygen speciesOverproduction of reactive oxygen speciesSocio-ecologic Factors Impacting Medication Adherence Trajectories in Patients With Drug-resistant Tuberculosis and Human Immunodeficiency Virus
Guzman K, Wolf A, Perumal R, Cummings M, Zulu M, Zelnick J, Friedland G, Amico K, Reis K, Cheung Y, Daftary A, Seepamore B, Naidoo K, O'Donnell M. Socio-ecologic Factors Impacting Medication Adherence Trajectories in Patients With Drug-resistant Tuberculosis and Human Immunodeficiency Virus. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a1036-a1036. DOI: 10.1164/ajrccm.2025.211.abstracts.a1036.Peer-Reviewed Original ResearchPhospholipid scramblase 1: a frontline defense against viral infections
Yang A, Norbrun C, Sorkhdini P, Zhou Y. Phospholipid scramblase 1: a frontline defense against viral infections. Frontiers In Cellular And Infection Microbiology 2025, 15: 1573373. PMID: 40248364, PMCID: PMC12003403, DOI: 10.3389/fcimb.2025.1573373.Peer-Reviewed Original ResearchConceptsPhospholipid scramblase 1Human immunodeficiency virusInfluenza A virusToll-like receptor 9Human T-cell leukemia virus type 1Epstein-Barr virusHepatitis B virusInterferon-stimulated genesViral infectionHuman cytomegalovirusVirus type 1Antiviral activityTranslocation of phospholipidsFrontline defenseTransactivation of human immunodeficiency virusImmunodeficiency virusActivation of JAK/STAT pathwayImmune cellsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2A virusB virusReceptor 9Respiratory syndrome coronavirus 2Entry of severe acute respiratory syndrome coronavirus 2Design and Characterization of Inhibitors of Cell-Mediated Degradation of APOBEC3G That Decrease HIV-1 Infectivity
Sawyer A, Vaca C, Malik N, Clerc I, Craft J, Hudson H, Scholtés G, Schiltz G, Roh M, Song C, D’Aquila R. Design and Characterization of Inhibitors of Cell-Mediated Degradation of APOBEC3G That Decrease HIV-1 Infectivity. Viruses 2025, 17: 514. PMID: 40284957, PMCID: PMC12031279, DOI: 10.3390/v17040514.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDecreased HIV-1 infectivitySpread of human immunodeficiency virusLevels of A3GHIV-producing cellsHIV-1 infectionA3GDecreased viral infectivityDegradation of A3GDegradation of APOBEC3GResistance-conferring mutationsInfectivity of virionsAnti-HIV therapeuticsViral infectivity factorImmunodeficiency virusCell-intrinsic defenseViral infectionAPOBEC3GCatalytic polypeptide-like 3Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3Infectivity factorInfectionA3G/FVifViral proteinsPilot Findings From the First Legalized Mobile Retail Pharmacy Clinic in the United States for Infectious Disease Treatment and Prevention Tailored to Reach People Who Use Drugs
Tarfa A, Di Paola A, Frank C, Schultheis A, Brooks R, Shenoi S, Springer S. Pilot Findings From the First Legalized Mobile Retail Pharmacy Clinic in the United States for Infectious Disease Treatment and Prevention Tailored to Reach People Who Use Drugs. Open Forum Infectious Diseases 2025, 12: ofaf200. PMID: 40276721, PMCID: PMC12019630, DOI: 10.1093/ofid/ofaf200.Peer-Reviewed Original ResearchHuman immunodeficiency virusHepatitis C virusOpioid use disorderAntiretroviral therapyViral loadHepatitis C virus viral loadTested HIVHuman immunodeficiency virus diagnosisSexually transmitted infection testingHepatitis C virus antibodyModerate to severe opioid use disorderDirect-acting antiviralsSevere opioid use disorderHIV antiretroviral therapyInfectious disease treatmentHCV VLImmunodeficiency virusPreexposure prophylaxisCommunity health workersPilot findingsC virusPostexposure prophylaxisHCV testingPositive testSubstance use disordersLipid Peroxidation and Glutathione Levels Among People Living With HIV Co‐infected With Human Coronaviruses in Ghana
Amegashie E, Kwayisi‐Darkwah C, Adusei‐Poku M, Sikeola R, Ativi L, Ahene A, Atampugbire G, Tagoe E, Paintsil E, Torpey K, Quaye O. Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co‐infected With Human Coronaviruses in Ghana. Journal Of Medical Virology 2025, 97: e70301. PMID: 40110873, DOI: 10.1002/jmv.70301.Peer-Reviewed Original ResearchMeSH KeywordsAdultCoinfectionCoronavirus InfectionsCross-Sectional StudiesCyclopropanesDideoxyadenosineDideoxynucleosidesFemaleGhanaGlutathioneHeterocyclic Compounds, 3-RingHIV InfectionsHumansLipid PeroxidationMaleMalondialdehydeMiddle AgedOxazinesOxidative StressPiperazinesProspective StudiesPyridonesYoung AdultConceptsHuman immunodeficiency virusHuman immunodeficiency virus co-infectionCo-InfectionGSH levelsART-experienced individualsPLWH co-infectedHuman coronavirusesHIV Co-InfectionHIV-negative individualsMalondialdehyde levelsOxidative stressOxidative stress markersIncreased MDA levelsCross-sectional studyOro-pharyngeal swabsImmunodeficiency virusGhanaian patientsMono-infectionReduced GSH levelsTreatment strategiesPlasma samplesDisease severityMDA levelsStress markersTailored monitoringHIV, smoking, and the brain: a convergence of neurotoxicities
Orlinick B, Farhadian S. HIV, smoking, and the brain: a convergence of neurotoxicities. AIDS Research And Therapy 2025, 22: 13. PMID: 39915881, PMCID: PMC11804093, DOI: 10.1186/s12981-025-00714-y.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusCholinergic anti-inflammatory pathwayAnti-inflammatory pathwayNeurocognitive impairmentTobacco smokeEffect of human immunodeficiency virusEffects of tobacco smokingNeurotoxic effectsBrain volume changesClinically significant impactIncreased oxidative stressImmunodeficiency virusAlpha7 nicotinic acetylcholine receptorPWHBrain regionsMicroglial activationCognitive functionBrain healthIncreased neuroinflammationNeuronal apoptosisTherapeutic targetAcetylcholine receptorsGeneral populationNeurotoxicitySmokingDistal Radius Fracture in the Setting of Human Immunodeficiency Virus: Management and Adverse Events
Hosseini H, Kammien A, Bach K, Allam O, Grauer J, Colen D. Distal Radius Fracture in the Setting of Human Immunodeficiency Virus: Management and Adverse Events. The Journal Of Hand Surgery 2025, 50: 451-458. PMID: 39895439, DOI: 10.1016/j.jhsa.2024.12.017.Peer-Reviewed Original ResearchHuman immunodeficiency virusDistal radius fracturesHuman immunodeficiency virus statusAntiretroviral therapyAdverse eventsRadius fracturesTreatment modalitiesOpen treatmentImmunodeficiency virusClosed treatmentHIV-negative patientsHIV-negative cohortAssociated with treatment modalityYear of fractureAntiretroviral therapy statusManagement of distal radius fracturesElevated fracture riskRate of malunionAssociated with greater incidenceModifiable risk factorsNational administrative databaseExperience adverse eventsChi-square testPrognostic IIFracture riskStructural insights into HIV-2 CA lattice formation and FG-pocket binding revealed by single-particle cryo-EM
Cook M, Freniere C, Wu C, Lozano F, Xiong Y. Structural insights into HIV-2 CA lattice formation and FG-pocket binding revealed by single-particle cryo-EM. Cell Reports 2025, 44: 115245. PMID: 39864060, PMCID: PMC11912512, DOI: 10.1016/j.celrep.2025.115245.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHIV-2Features of human immunodeficiency virusHIV-2 CAHost factor interactionsImmunodeficiency virusHIV-1Human immunodeficiency virus capsidFunctionalized liposomesCapsid proteinHigh-resolution structuresSingle-particle cryo-EMCA assemblyCA hexamersFactor interactionsViral genomeCA latticeAutopsy: Infectious and Serious Communicable Diseases
Gill J, Brooks E. Autopsy: Infectious and Serious Communicable Diseases. 2025, 455-467. DOI: 10.1016/b978-0-443-21441-7.00021-2.Peer-Reviewed Original ResearchHuman immunodeficiency virusViral hepatitis BRisk of occupational infectionOccupational infectionInfection control practicesForensic autopsy populationImmunodeficiency virusHepatitis BInfectious disease testingTuberculosis infectionInfectious disease test resultsDiagnostic accuracyPostexposure managementInfectionSARS-CoV-2Autopsy populationAutopsyMicrobiological testsEbola virusPostmortem examinationDisease testingInfectious diseasesLaboratory personnelPreventive measuresDeath
2024
Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS)
Yan L, Henegar C, Marconi V, Gordon K, Hicks C, Vannappagari V, Justice A, Aslan M. Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS). AIDS Research And Therapy 2024, 21: 96. PMID: 39709467, PMCID: PMC11662819, DOI: 10.1186/s12981-024-00681-w.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmidesAnti-HIV AgentsCohort StudiesDarunavirDrug Therapy, CombinationFemaleHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV InfectionsHIV Integrase InhibitorsHumansMaleMiddle AgedOxazinesPiperazinesPyridazinesPyridonesQuinolonesRaltegravir PotassiumTreatment OutcomeVeteransViral LoadConceptsVeterans Aging Cohort StudyRAL-based regimenAntiretroviral therapyAging Cohort StudyCohort studyOdds of virologic suppressionIntegrase strand transfer inhibitorsDarunavir-based regimensDolutegravir-based regimensDTG-based regimensAntiretroviral therapy experienceHuman immunodeficiency virusDTG-based regimenInverse probability of treatment weightingStrand transfer inhibitorsBackgroundReal-world dataProbability of treatment weightingMethodsThis cohort studyVirologic suppressionVirological failureVirological effectImmunodeficiency virusDarunavir/ritonavirClinical outcomesRegimen initiationTuberculosis Preventive Treatment for Pregnant People With Human Immunodeficiency Virus in South Africa: A Modeling Analysis of Clinical Benefits and Risks
Rosen L, Thielking A, Dugdale C, Montepiedra G, Kalk E, Kim S, LaCourse S, Mathad J, Freedberg K, Horsburgh C, Paltiel A, Wood R, Ciaranello A, Reddy K. Tuberculosis Preventive Treatment for Pregnant People With Human Immunodeficiency Virus in South Africa: A Modeling Analysis of Clinical Benefits and Risks. Clinical Infectious Diseases 2024, ciae508. PMID: 39544107, DOI: 10.1093/cid/ciae508.Peer-Reviewed Original ResearchAdverse pregnancy outcomesHuman immunodeficiency virusRisk of stillbirthFetal/infant deathImmunodeficiency virusHigher risk of LBWMaternal CD4 cell countCD4 cell countMonths of isoniazidRisk of LBWPregnant peopleHigher-risk scenarioTuberculosis preventive treatmentIsoniazid-rifapentineAntiretroviral therapyPregnancy outcomesClinical benefitPrimary outcomeCombined deathPreventive treatmentCell countHigh riskStillbirthPregnancyInternational guidelinesInducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation
Ding H, Nguyen H, Li W, Deshpande A, Zhang S, Jiang F, Zhang Z, Anang S, Mothes W, Sodroski J, Kappes J. Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation. Journal Of Virology 2024, 98: e01720-24. PMID: 39508605, PMCID: PMC11650979, DOI: 10.1128/jvi.01720-24.Peer-Reviewed Original ResearchHuman immunodeficiency virusEnv trimersNeutralizing antibodiesHIV-1Virus-like particlesEnvelope glycoproteinEnv conformationImmunodeficiency virusInducible cell linesCell linesImmune systemEffective HIV/AIDS vaccineHIV-1 persistenceHuman immunodeficiency virus particlesEnvelope glycoprotein spikeHIV-1 EnvPoorly neutralizing antibodiesHIV-like particlesHIV-1 particlesDefective virus-like particlesHost immune systemEnv immunogensHIV/AIDS vaccineCreation of stable cell linesHost cell receptorsAntibiotic resistance and draft genome profiles of 10 Streptococcus pneumoniae and 3 Streptococcus pseudopneumoniae strains isolated from the nasopharynx of people living with human immunodeficiency virus in Ghana
Ativi L, Adusei-Poku M, Boateng W, Owusu-Nyantantakyi C, Danso J, Oclu A, Bortey A, Amuasi G, Tabi B, Paintsil E, Torpey K, Dayie N, Egyir B. Antibiotic resistance and draft genome profiles of 10 Streptococcus pneumoniae and 3 Streptococcus pseudopneumoniae strains isolated from the nasopharynx of people living with human immunodeficiency virus in Ghana. Microbiology Resource Announcements 2024, 13: e00505-24. PMID: 39365088, PMCID: PMC11556032, DOI: 10.1128/mra.00505-24.Peer-Reviewed Original ResearchAntimicrobial resistanceWhole-genome profilingGenomic dataAntibiotic resistanceBacteria speciesStreptococcus pneumoniae</i>Streptococcus speciesGenomic profilingHuman immunodeficiency virusSpeciesStreptococcus pneumoniaeAntimicrobial resistance surveillance effortsImmunodeficiency virusSurveillance effortsMiddle-income countriesStrainResistanceEstimating pneumococcal carriage dynamics in adults living with HIV in a mature infant pneumococcal conjugate vaccine programme in Malawi, a modelling study
Phiri J, Sibale L, Mlongoti L, Mitole N, Kusakala A, Khwiya M, Kayembe T, Lisimba E, Kapwata P, Malisita K, Chaguza C, Ferreira D, Thindwa D, Jambo K. Estimating pneumococcal carriage dynamics in adults living with HIV in a mature infant pneumococcal conjugate vaccine programme in Malawi, a modelling study. BMC Medicine 2024, 22: 419. PMID: 39334289, PMCID: PMC11438070, DOI: 10.1186/s12916-024-03631-5.Peer-Reviewed Original ResearchConceptsNon-PCV13 serotypesAntiretroviral therapyPneumococcal carriage prevalencePneumococcal carriageCarriage prevalenceHIV- adultsStudy groupCarriage acquisitionDetect pneumococcal carriageAntiretroviral therapy durationHuman immunodeficiency virusSocial economic statusPneumococcal conjugate vaccination programmeMultivariate longitudinal analysesPCV13 serotypesProlonged carriageImmunodeficiency virusMedian ageHIV individualsNasopharyngeal clearancePneumococcal serotypesALWHIVLatex agglutinationCulture microbiologyPoint prevalenceTrajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic
Liberman A, Kurmanalieva A, Biibosunova D, Shumskaya N, Ivasiy R, Bromberg D, Madden L, Altice F. Trajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic. Global Health Economics And Sustainability 2024, 2: 2536. PMID: 40212662, PMCID: PMC11985161, DOI: 10.36922/ghes.2536.Peer-Reviewed Original ResearchOpioid agonist therapyHuman immunodeficiency virusMortality of human immunodeficiency virusOpioid agonist therapy programsOpioid use disorderMethadone programsHIV prevention strategiesAgonist therapyImmunodeficiency virusClinical protocolsEffective treatmentUse disorderNeighboring countriesHIV preventionKyrgyz RepublicMethadoneOpioidCentral AsiaIncreased state supportCentral Asian countriesDrugCarceral systemInternational donorsLocal news coveragePolitical challengesUnderstanding emerging and re-emerging viruses to facilitate pandemic preparedness
Zapatero-Belinchón F, Kumar P, Ott M, Schwartz O, Sigal A. Understanding emerging and re-emerging viruses to facilitate pandemic preparedness. Nature Microbiology 2024, 9: 2208-2211. PMID: 39198691, DOI: 10.1038/s41564-024-01789-5.Peer-Reviewed Original ResearchVeteran's Health Administration HIV Care Continuum: 2019 vs 2022
Maier M, Beste L, Lowy E, Hauser R, Van Epps P, Yakovchenko V, Rogal S, Chartier M, Ross D. Veteran's Health Administration HIV Care Continuum: 2019 vs 2022. Open Forum Infectious Diseases 2024, 11: ofae382. PMID: 39086463, PMCID: PMC11288371, DOI: 10.1093/ofid/ofae382.Peer-Reviewed Original ResearchHuman immunodeficiency virusHIV care continuumViral suppressionVL resultsViral loadCare continuumFactors associated with viral suppressionTime of HIV diagnosisHuman immunodeficiency virus careRetrospective cohort analysisMultivariate logistic regressionVirologic suppressionImmunodeficiency virusHIV diagnosisVeterans Health AdministrationReceipt of careCohort analysisHealth care institutionsPWHCare qualityVHA careHealth AdministrationCare institutionsCareVHAAdvances in HIV Management During Pregnancy and Infant Feeding
Espinal M, Yee L, Fisher S. Advances in HIV Management During Pregnancy and Infant Feeding. Infectious Disease Clinics Of North America 2024, 38: 423-452. PMID: 38969531, DOI: 10.1016/j.idc.2024.06.005.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAntiretroviral therapyHuman immunodeficiency virus managementInfant feedingChoice of infant feeding methodEvidence of safetyImmunodeficiency virusInfant feeding methodClinical trialsPharmacokinetic dataPregnant individualsPregnancyInfantsTesting guidanceTherapyBreastfeedingEfficacyFeeding methodTrialsHIV and Substance Use Disorders
Lier A, Tarfa A, Shenoi S, Kuo I, Springer S. HIV and Substance Use Disorders. Infectious Disease Clinics Of North America 2024, 38: 599-611. PMID: 38960783, PMCID: PMC11410345, DOI: 10.1016/j.idc.2024.06.003.Peer-Reviewed Original ResearchHuman immunodeficiency virusSubstance use disordersEvidence-based public health effortsHuman immunodeficiency virus acquisitionHuman immunodeficiency virus incidenceRisk of HIV acquisitionUntreated substance use disordersPoor HIV outcomesAdherence to HIV antiretroviral therapyHIV antiretroviral therapyPublic health effortsInjection drug useAntiretroviral therapyHIV acquisitionImmunodeficiency virusHIV outcomesHealth effortsTreatment strategiesIncreased riskDrug useSubstance useDrugAmericanRiskPersons
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply